Q1 2026 · 13F-HR
Euclidean Capital LLCholdings as filed
Filed 2026-05-15 · accession 0001012975-26-000442
$392.3M
Reported value
10
Positions
2026-03-31
Period end
The Brief · Euclidean Capital LLC · Q1 2026
AI · grounded in 13F
Euclidean Capital LLC closed its position in SPY, reducing its holdings by $2.8M. The fund also exited its position in RAPT for a total of $2.8M. Additionally, the firm accumulated shares of VEU, increasing its position by 8.47%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922042775 | VEU | VANGUARD INTL EQUITY INDEX F | $243.6M | 62.1% | 3,243,484 | Common | SOLE |
| 922908744 | VTV | VANGUARD INDEX FDS | $102.0M | 26.0% | 520,000 | Common | SOLE |
| 46429B598 | INDA | ISHARES TR | $17.3M | 4.41% | 369,600 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $12.5M | 3.20% | 989,410 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $7.5M | 1.92% | 1,573,761 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $3.3M | 0.83% | 2,627,643 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $2.8M | 0.72% | 1,307,858 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $2.6M | 0.65% | 87,696 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $703,274 | 0.18% | 1,015,705 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $2,733 | 0.00% | 170,833 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.